Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors

Biochemical Pharmacology

Volumn 79, Issue 8, 2010, Pages 1100-1107

  Reuveni, Debby ^a   Halperin, Drora ^a   Fabian, Ina ^a   Tsarfaty, Galia ^b   Askenasy, Nadir ^c   Shalit, Itamar ^a,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Angiogenesis; Chemotherapy; Irinotecan; Moxifloxacin

Indexed keywords

CD31 ANTIGEN; INTERLEUKIN 8; IRINOTECAN; KI 67 ANTIGEN; MOXIFLOXACIN; NUCLEAR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL STRAIN HT29; COLON CARCINOMA; CONTROLLED STUDY; DISEASE MODEL; DOPPLER ECHOGRAPHY; DRUG POTENTIATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TREATMENT OUTCOME; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; AZA COMPOUNDS; CAMPTOTHECIN; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; HUMANS; INTERLEUKIN-8; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; QUINOLINES; ULTRASONOGRAPHY, DOPPLER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77249101970     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.12.001     Document Type: Article

References (36)

1. Bidard F.C., Tournigand C., André T., Mabro M., Figer A., Cervantes A., et al. Efficacy of FOLFIRI-3 (irinotecan D1, D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Ann Oncol 2009, 20:1042-1047.
2. Fuchs C.S., Marshall J., Mitchell E., Wierzbicki R., Ganju V., Jeffery M., et al. Randomized controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007, 25:4779-4786.
3. Hind D., Tappenden P., Tumur I., Eggington S., Sutcliffe P., Ryan A. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2008, 12:1-162.
4. Shalit I., Nasrallah N., Bar-On S., Rabau M. In vitro effect of ciprofloxacin and ofloxacin on murine and human colon carcinoma cell lines. Drugs 1995, 49(Suppl. 2):296-297.
5. Herold C., Ocker M., Ganslmayer M., Gerauer H., Hahn E.G., Schuppan D. Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer 2002, 86:443-448.
6. Aranha O., Grignon R., Fernandes N., McDonnell T.J., Wood D.P., Sarkar F.H. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. Int J Oncol 2003, 22:787-794.
7. Fabian I., Haite D., Levitov A., Halperin D., Shalit I. Moxifloxacin enhances the antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in THP-1 and Jurkat cells. Br J Cancer 2006, 95:1038-1046.
8. Thadepalli H., Salem F., Chuah S.K., Gollapudi S. Antitumor activity of trovafloxacin in an animal model. In Vivo 2005, 19:269-276.
9. Zehavi-Willner T., Shalit I. The inhibitory effect of ciprofloxacin on proliferation of a murine bladder carcinoma cell line. J Antimicrob Chemother 1992, 29:323-328.
10. Anderson V.A., Osheroff N. Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. Curr Des Pharmacol 2001, 7:339-355.
11. Bromberg K.D., Burgin A.B., Osheroff N. Quinolone action against human topoisomerase II alpha: stimulation of enzyme-mediated double-stranded DNA cleavage. Biochemistry 2003, 42:3393-3398.
12. Reuveni D., Halperin D., Shalit I., Priel E., Fabian I. Quinolones as enhancers of camptothecin-induced cytotoxic and anti-topoisomerase I effects. Biochem Pharmacol 2008, 75:1272-1281.
13. Shalit I., Horev L., Fabian I., Blau H., Kariv N., Shechtman I., et al. Immunomodulatory and protective effects of moxifloxacin against Candida albicans induced bronchopneumonia in cyclophosphamide injected mice. Antimicrob Agents Chemoth 2002, 46:2442-2449.
14. Britten C.D., Hilsenbeck S.G., Eckhardt S.G., Marty J., Mangold G., MacDonald J.R., et al. Enhanced antitumour activity of 6-droxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumour xenograft model. Cancer Res 1999, 59:1049-1053.
15. Park R., Chang C.C., Liang Y.C., Chung Y., Henry R.A., Lin E., et al. Systemic treatment with tetra-o-methyl nordihydroguaiaretic acid suppresses the growth of human xenograft tumours. Clin Cancer Res 2005, 11:4601-4609.
16. Tsarfaty G., Stein G.Y., Moshitch-Moshkovitz S., Kaufman D.W., Cao B., Resau J.H., et al. HGF/SF increases tumour blood volume: a novel tool for the in vivo functional molecular imaging of met. Neoplasia 2006, 8:344-352.
17. Gee M.S., Saunders H.M., Lee J.C., Sanzo J.F., Jenkins W.T., Evans S.M., et al. Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations. Cancer Res 2001, 61:2974-2982.
18. Lahat G., Halperin D., Barazovsky E., Shalit I., Rabau M., Fabian I. The immunomodulatory effects of ciprofloxacin in TNBS induced colitis in mice. Inflamm Bowel Disease 2007, 13:557-565.
19. Tarasenko N., Nudelman A., Tarasenko I., Entin-Meer M., Hass-Kogan D., Inbal A., et al. Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). Clin Exp Metastasis 2008, 25:703-716.
20. Shinohara H., Killion J.J., Kuniyasu H., Kumar R., Fidler I.J. Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the peptide JBT 3002. Clin Cancer Res 1998, 4:2053-2063.
21. El-Salhy M., Hilding L., Royson H., Tjomsland V. Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer. Int J Oncol 2005, 27:687-691.
22. Scholzen T., Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000, 182:311-322.
23. Hosaka N., Ichikawa Y., Ishikawa T., Nagashima Y., Kunisaki C., Takahashi M., et al. Correlation of immunohistochemical p53 labeling index with inhibition rate in chemosensitivity test in gastric and colon cancer. Anticancer Res 2001, 21:229-235.
24. Duncan G.S., Andrew D.P., Takimoto H., Kaufman S.A., Yoshida H., Spellberg J., et al. Genetic evidence for functional redundancy of platelet/endothelial cell adhesion molecule-1 (PECAM-1): CD31-deficient mice reveal PECAM-1-dependent and PECAM-1-independent functions. J Immunol 1999, 162:3022-3030.
25. Tabarrini O., Cecchetti V., Fravolini A., Nocentini G., Barzi A., Sabatini S., et al. Design and synthesis of modified quinolones as antitumoral acridones. J Med Chem 1999, 42:2136-2144.
26. Rajabalian S., Foroumadi A., Shafiee A., Emami S. Functionalized N(2-oxyiminoethyl) piperazinyl quinolones as new cytotoxic agents. J Pharm Sci 2007, 10:153-158.
27. Chu D.T., Hallas R., Tanaka S.K., Alder J., Balli D., Plattner J.J. Synthesis and antitumor activities of tetracyclic quinolone antineoplastic agents. Drugs Exp Clin Res 1994, 20:177-183.
28. Sissi C., Palumbo M. The quinolone family: from antibacterial to anticancer agents. Curr Med Chem Anticancer Agents 2003, 3:439-450.
29. Donnelly E.F., Geng L., Wojcicki W.E., Fleischer A.C., Hallahan D.E. Quantified power Doppler US of tumour blood flow correlates with microscopic quantification of tumor blood vessels. Radiology 2001, 219:166-170.
30. Bocci G., Falcone A., Fioravanti A., Orlandi P., Di Paolo A., Fanelli G., et al. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 2008, 98:1619-1629.
31. Wildiers H., Guetens G., De Boeck G., Verbeken E., Landuyt B., Landuyt W., et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003, 88:1979-1986.
32. Tappenden P., Jones R., Paisley S., Carroll C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007, 11:1-128.
33. Popov I., Milicević M., Radosević-Jelić L.j. The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy. Acta Chir Iugosl 2008, 55:11-16.
34. Gartner E.M., Griffith K.A., Pan Q., Brewer G.J., Henja G.F., Merajver S.D., et al. A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. Invest New Drugs 2009, 27:159-165.
35. Dietrich J., Norden A.D., Wen P.Y. Emerging antiangiogenic treatments for gliomas-efficacy and safety issues. Curr Opin Neurol 2008, 21:736-744.
36. McCormack P.L., Keam S.J. Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs 2008, 68:487-506.